Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Liabilities and Shareholders Equity (2023 - 2025)

Kura Oncology (KURA) has disclosed Liabilities and Shareholders Equity for 3 consecutive years, with $738.4 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity fell 2.87% to $738.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.8 billion through Dec 2025, up 21.92% year-over-year, with the annual reading at $738.4 million for FY2025, 2.87% down from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $738.4 million at Kura Oncology, up from $649.4 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $760.2 million in Q4 2024, with the low at $426.0 million in Q1 2023.
  • Average Liabilities and Shareholders Equity over 3 years is $580.4 million, with a median of $534.5 million recorded in 2024.
  • The sharpest move saw Liabilities and Shareholders Equity skyrocketed 69.32% in 2024, then dropped 2.87% in 2025.
  • Over 3 years, Liabilities and Shareholders Equity stood at $448.9 million in 2023, then skyrocketed by 69.32% to $760.2 million in 2024, then dropped by 2.87% to $738.4 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $738.4 million, $649.4 million, and $682.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.